Core Viewpoint - The company, Guoke Hengtai, clarified that it has not engaged in cell immunotherapy-related business and has not disclosed any related announcements, emphasizing its commitment to focus on its core business and enhance its core competitiveness for high-quality development and mutual value enhancement for the company and its shareholders [1] Group 1 - The company has not initiated any cell immunotherapy-related business [1] - There are no related announcements disclosed by the company [1] - The company aims to focus on its main business and improve its core competitiveness [1]

Group 1 - The core point of the article is the confirmation of the existence of Xiamen Guokai Hengtai Medical Technology Co., Ltd. as a wholly-owned subsidiary of Guokai Hengtai (301370.SZ) [2] - An investor inquired about the relationship between HeFu China and Guokai Hengtai, specifically regarding the doubling of HeFu China's value [2] - Guokai Hengtai responded on the investor interaction platform, affirming the existence of the subsidiary [2]

Core Viewpoint - The company, Guoke Hengtai (301370.SZ), has clarified that it is not engaged in cell immunotherapy-related business and has not disclosed any related announcements [1] Group 1 - The company will continue to focus on its main business and strive to enhance its core competitiveness [1] - The company aims to promote high-quality development and achieve a mutual enhancement of company value and shareholder value [1]

Group 1 - The core point of the article is that Guoke Hengtai has reported the number of its shareholders as of November 10, 2025, which stands at 18,047 [2]

Core Viewpoint - The company, Guokai Hengtai, is currently in the early research and exploration phase of its third-party manufacturing (CDMO) business in the medical device sector, which has not yet generated substantial revenue and does not impact the current operating performance of the company [1] Group 1 - The CDMO business is still in the preliminary research and exploration stage [1] - There is no significant revenue generated from the CDMO business at this time [1] - The current operating performance of the company is not affected by the CDMO business [1] Group 2 - The company will continue to monitor opportunities in the upstream manufacturing sector [1] - The company aims to steadily advance its related business in line with strategic development needs [1]

Group 1: Investment Value - The company positions itself as a comprehensive digital supply chain service provider for medical devices, moving beyond traditional distribution models [1] - The long-term strategic layout of "1+3+N" focuses on solidifying the core supply chain business while nurturing three new growth engines: digital business, technology transfer, and international expansion [1][2] - Strong partnerships with global companies like Boston Scientific and Medtronic enhance business stability and risk resilience [2] Group 2: Business Development and Market Trends - The Chinese medical device market is expected to grow due to rigid demand, strong policies, disruptive technologies, and a global perspective [4] - The company’s digital platform addresses traditional distribution challenges, ensuring stability and safety in clinical supply under procurement policies [4] - The company aims to provide comprehensive commercialization solutions, enhancing market influence for medical device manufacturers [2] Group 3: Capital Operations and Future Plans - Currently, there are no specific capital operation plans; future actions will depend on market conditions and strategic needs [3] - The company will utilize capital market tools to promote high-quality development when appropriate [3] Group 4: Digital Business and CDMO Progress - The company has achieved 100% online management of business processes and developed a digital solution for manufacturers, distributors, and hospitals [5][6] - The CDMO (Contract Development and Manufacturing Organization) business is still in the exploratory phase and does not currently impact short-term performance [6]

Core Viewpoint - The company, Guoke Hengtai, has recently received a patent certificate from the National Intellectual Property Administration for an invention related to medical device order processing methods and apparatus [2] Summary by Categories Company Announcement - Guoke Hengtai announced the receipt of an invention patent certificate for a medical device order processing method and apparatus [2]

Group 1 - The core point of the article is that Guokai Hengtai has received a patent for a medical device order processing method and device, which may enhance its competitive edge in the medical technology sector [1] - As of November 4, Guokai Hengtai's market capitalization is 5.1 billion yuan [1] - The revenue composition for Guokai Hengtai from January to June 2025 shows that vascular interventional treatment materials account for 71.09%, other products 14.58%, non-vascular interventional treatment materials 5.27%, orthopedic implant materials 5.12%, and oral products 2.25% [1] Group 2 - The article highlights a significant increase in overseas orders for a certain industry, with a 246% rise covering over 50 countries and regions [1] - Entrepreneurs are warning about the risk of cutthroat competition as some companies are selling products at a loss [1]

证券代码：301370 证券简称：国科恒泰 公告编号：2025-069 国科恒泰（北京）医疗科技股份有限公司 关于累计非重大诉讼、仲裁进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 6 日披露了《关于累计诉讼、仲裁情况的公告》（公告编号：2025-049），截至 本公告披露日，相关累计非重大诉讼、仲裁案件的进展情况如下： 一、已披露累计非重大诉讼、仲裁事项进展情况 公司于近日收到北京市大兴区人民法院《民事判决书》（（2025）京 0115 民 初 12619 号），判决被告百仕韦（长汀）医疗器械有限公司于判决生效后十日内向 国科恒佳（北京）医疗科技有限公司（以下简称"国科恒佳"）退还未发货货款 5,398,068.8 元及截止至 2022 年 9 月 14 日的利息 357,622.06 元，支付库存回购款 2,641,481.48 元及截止至 2022 年 9 月 14 日的利息 194,809.26 元，支付退货未退款 金额 261,036.97 元，支付超额 ...

证券代码：301370 证券简称：国科恒泰 公告编号：2025-070 国科恒泰（北京）医疗科技股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）于近日收到国 家知识产权局颁发的《发明专利证书》，具体情况如下： 发明名称：医疗器械订单处理方法及装置 专利类型：发明专利 专利申请日：2024 年 5 月 31 日 专利权人：国科恒泰（北京）医疗科技股份有限公司 授权公告日：2025 年 10 月 28 日 专利简介： 本申请实施例提供一种医疗器械订单处理方法及装置，方法包括：根据医疗器 械订单管理系统中历史订单数据确定正常订单的数据分布，根据设定异常检测模型 确定所述医疗器械订单管理系统中当前订单数据中与所述正常订单的数据分布存 在偏差的异常订单，并将所述异常订单设置为可抢订单；通过集成模型的输出层输 出可抢单客服；将所述可抢订单分配至所述可抢单客服的待处理工作页面，并在接 收到所述可抢单客服发送的清单请求后，将所述可抢订单的处理权限变更为该可抢 单客服；本申请能够有 ...